All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

When having a liver transplant, patients routinely receive antibiotics to prevent infections. However, some people carry a bug in their gut called CPE (carbapenemase-producing Enterobacterales). These bacteria can resist many common antibiotics. While they often cause no symptoms in the gut, they can lead to dangerous infections after major surgery when the immune system is weak. This trial compares two approaches: standard preventative antibiotics versus targeted antibiotics chosen specifically to fight CPE. Researchers will monitor patients for two weeks after surgery to see which approach better prevents post-transplant infections. Patients will also be followed for up to 90 days to check general recovery, track any side effects, and see how their natural gut bacteria recover. The goal is to make liver transplants safer for people carrying these hard-to-treat bacteria.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Enrolment target
168
Start
31 Aug 2026

What is this study about?

A liver transplant is a major operation that gives people with severe liver disease a second chance at life. After the surgery, patients must take medicines that calm their immune system so their body does not reject the new liver. Because their natural defences are lowered, avoiding bacterial infections is critical. Before and during surgery, doctors give preventative antibiotics through a drip to protect the patient.

Some patients carry a family of bacteria in their gut known as CPE. In healthy individuals, these bugs usually live harmlessly without causing any symptoms. However, CPE are resistant to carbapenems, which are normally some of the strongest antibiotics doctors have. If CPE enters the bloodstream or the surgical area after a transplant, it can cause severe infections that are very difficult to treat.

In this clinical trial, doctors are testing whether a 'targeted' preventative approach works better than standard preventative care. Instead of ordinary antibiotics, the targeted group receives newer or specific medicines matched to fight CPE. Researchers will closely check whether this prevents infections during the critical first two weeks after the transplant.

Taking part helps doctors understand how best to protect vulnerable transplant patients in the future. The trial also studies how these medications affect healthy gut bacteria and monitors patient health and recovery up to three months after surgery.

Key takeaways

  • The trial tests targeted antibiotics to prevent drug-resistant CPE infections after liver transplantation.
  • It involves adults aged 18 and over who carry CPE bacteria in their gut.
  • Antibiotics are given through a drip around the time of the transplant surgery.
  • Patient health and gut bacteria are monitored for up to 90 days after surgery.
  • Participation is entirely voluntary and standard surgical care remains unchanged.

Who may be eligible?

This study is open to adults aged 18 and older who are preparing to undergo a liver transplant and have tested positive for carrying CPE bacteria in their gut.

Patients of any gender can join, provided they are already scheduled for a liver transplant at a participating hospital centre. Your transplant team will test your gut bacteria using routine swabs or stool samples before surgery to check if you carry CPE.

People who have severe allergies to the specific trial antibiotics, or those who cannot safely receive the study medications, will not be able to take part. Your care team will review your complete medical history to ensure joining is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I am on the waiting list or scheduled for a liver transplant.
  3. A swab or test has shown that I carry CPE bacteria in my gut.
  4. I do not have known severe allergies to the study antibiotics.
  5. I am willing to attend follow-up checks for up to 90 days after surgery.
Answer every question to see your result.

What does participation involve?

If you take part, your transplant operation and general medical care will proceed as normal. Around the time of your surgery, you will receive either standard preventative antibiotics or targeted antibiotics designed to fight CPE. These medicines are given through a drip (infusion) into a vein before and during the operation, and briefly afterwards.

During your hospital stay, doctors will closely monitor your recovery, checking your blood and kidney health for any side effects. You will have routine follow-up assessments at 14 days, 30 days, 60 days, and 90 days after your transplant. During these visits, the team will check for signs of infection, review your recovery, and take routine samples (such as blood or stool tests) to see if CPE is still present and how your gut bacteria are healing. In total, your participation in the study lasts about three months.

Potential risks and benefits

A potential benefit of joining is receiving antibiotics specifically tailored to protect against resistant bacteria, which may lower your risk of serious infection after surgery. You will also receive extra monitoring from the research team. However, like all medications, the antibiotics can cause side effects. These may include mild reactions like sickness or diarrhoea, or rarer problems affecting the kidneys, nerves, or allergic reactions. Taking part is completely voluntary. You are free to say no or leave the study at any time, and your decision will never affect your transplant care or your relationship with your medical team.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Italy

Common questions

What is CPE?

CPE stands for carbapenemase-producing Enterobacterales. They are gut bacteria that have developed resistance to carbapenems, a powerful group of antibiotics.

Does carrying CPE mean I am ill right now?

No. Many people carry CPE in their digestive system without feeling sick. Doctors call this being 'colonised'. It only becomes an issue if the bacteria get into wounds, the blood, or urine.

Will taking part change how my transplant surgery is done?

No. Your surgical procedure and organ transplant care will remain exactly the same. The trial only changes the preventative antibiotics you receive around the time of surgery.

How will I receive the antibiotics?

The antibiotics are given as an infusion through a drip directly into your vein before, during, and briefly after your operation.

What happens if I decide not to take part?

You will receive the standard NHS care and standard preventative antibiotics used at your hospital. Your place on the transplant list and quality of care will not change.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.